Elahere (mirvetuximab soravtansine-gynx) / ImmunoGen, AbbVie, Takeda, Huadong Medicine  >>  Phase 3
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Elahere (mirvetuximab soravtansine-gynx) / AbbVie
FORWARD I, NCT02631876: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Checkmark Pooled analysis data from trials for ovarian cancer at ESMO 2022
Sep 2022 - Sep 2022: Pooled analysis data from trials for ovarian cancer at ESMO 2022
Checkmark Presentation from FORWARD I study for platinum-resistant ovarian cancer at ESMO 2022
Sep 2022 - Sep 2022: Presentation from FORWARD I study for platinum-resistant ovarian cancer at ESMO 2022
Checkmark Data from FORWARD I trial for platinum-resistant FRa-positive advanced epithelial ovarian cancer at ESMO 2022
More
Completed
3
366
Europe, Canada, US, RoW
Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
ImmunoGen, Inc., Gynecologic Oncology Group
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
01/19
01/20
SORAYA, NCT04296890 / 2020-000179-19: A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Jan 2024 - Dec 2023: Data from SORAYA trial for ovarian cancer at SGO 2023
Checkmark Approved for 2L treatment in patients with FRα high platinum-resistant ovarian cancer based on SORAYA trial
Nov 2022 - Nov 2022: Approved for 2L treatment in patients with FRα high platinum-resistant ovarian cancer based on SORAYA trial
Checkmark Data from SORAYA trial for ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from SORAYA trial for ovarian cancer at IGCS 2022
More
Completed
3
106
Europe, US, RoW
Mirvetuximab Soravtansine, IMGN853, MIRV
ImmunoGen, Inc.
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
11/21
11/22
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Recruiting
3
35
RoW
Mirvetuximab Soravtansine, IMGN853, MIRV
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
04/23
12/23
MIRASOL, NCT04209855 / 2019-003509-80: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Jan 2023 - Dec 2023: Market entry in ex-US for platinum-resistant ovarian cancer
Hourglass Jan 2023 - Mar 2023 : Top-line data from MIRASOL trial for high-grade epithelial ovarian cancer
Hourglass Jul 2022 - Sep 2022 : Approval for high-grade epithelial ovarian cancer (based on MIRASOL trial)
Completed
3
453
Europe, Canada, US, RoW
Mirvetuximab Soravtansine, MIRV, IMGN853, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
AbbVie, Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/23
10/24
FRAmework-01, NCT07213804: A Two-Part Phase 3 Study of LY4170156 in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Recruiting
3
1080
Europe, Canada, Japan, US, RoW
LY4170156, sofetabart mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin, MIRV, Bevacizumab, Carboplatin
Eli Lilly and Company, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
04/28
08/31
NCT07218809: AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Recruiting
3
1100
Europe, Canada, Japan, US, RoW
AZD5335, Mirvetuximab Soravtansine (MIRV), Elahere, Paclitaxel, Taxol; Onxol, Pegylated liposomal Doxorubicin (PLD), Doxil; Caelyx, Topotecan, Hycamtin
AstraZeneca, European Network of Gynecological Oncological Trial Groups (ENGOT), GOG Foundation, Inc. (GOG Foundation), Ventana Medical Systems, Inc
Epithelial Ovarian Cancer
11/28
05/30
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
520
Europe, Canada, Japan, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
2015-004060-11: A study to test Mirvetuximab Soravtansine (IMGN853) aganist doctor's choice of cancer medicines in women with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer

Completed
2/3
333
Europe, RoW
Mirvetuximab Soravtansine, Pegylated Liposomal Doxorubicin, Paclitaxel, Topotecan, IMGN853, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Caelyx 2mg/ml concentrate for solution for infusion, Paclitaxel 6mg/ml Concentrate For Solution For Infusion, Topotecan 4 mg/4 ml concentrate for solution for infusion
ImmunoGen, Inc., IMMUNOGEN, INC., ImmunoGen, Inc., ImmunoGen Inc.
Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer, Cancer of ovary and related organs, Diseases [C] - Cancer [C04]
 
 

Download Options